2014
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome
Cronin CA, Sheth KN, Zhao X, Messé SR, Olson DM, Hernandez AF, Bhatt DL, Schwamm LH, Smith EE. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. Stroke 2014, 45: 2745-2749. PMID: 25104846, DOI: 10.1161/strokeaha.114.005443.Peer-Reviewed Original ResearchConceptsAdditional exclusion criteriaExclusion criteriaDiabetes mellitusAmerican Heart Association/American Stroke Association guidelinesEuropean Cooperative Acute Stroke StudyAmerican Stroke Association guidelinesSymptomatic intracranial hemorrhageWorse hospital outcomesHealth Stroke ScalePercent of patientsHistory of strokeOral anticoagulant treatmentCertain patient groupsAcute Stroke StudyTreatment time windowHour windowECASS IIIGuidelines-StrokePrior strokeAnticoagulant treatmentHospital outcomesStroke ScaleIschemic strokeSymptom onsetIncreased risk
2012
Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke
Messé S, Fonarow G, Smith E, Kaltenbach L, Olson D, Kasner S, Schwamm L. Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Circulation Cardiovascular Quality And Outcomes 2012, 5: 321-326. PMID: 22550132, DOI: 10.1161/circoutcomes.111.964064.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overEuropeFemaleFibrinolytic AgentsGuideline AdherenceHumansInfusions, IntravenousLinear ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOutcome and Process Assessment, Health CarePractice Guidelines as TopicStrokeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment OutcomeUnited StatesConceptsAcute ischemic strokeEuropean Cooperative Acute Stroke Study (ECASS) IIIECASS IIITreatment of patientsUse of tPAEligible patientsHours of AISProportion of patientsStudy IIITissue-type plasminogen activatorGuidelines-StrokeIschemic strokeMedian doorNeedle timePatientsClinical practiceTreatment ratesPlasminogen activatorSignificant increaseHoursLater time windowAdverse affectsTPATreatmentProportion